Characteristics of Patients With Sertoli and Leydig Cell Testis Neoplasms From a National Population-Based Registry

Clin Genitourin Cancer. 2017 Apr;15(2):e263-e266. doi: 10.1016/j.clgc.2016.08.001. Epub 2016 Aug 12.


Introduction: Sertoli and Leydig cell tumors (SCT and LCT) are uncommon testis neoplasms. Data regarding patient demographics and outcomes are limited to small series. We further characterized these tumors using a large cancer database.

Methods: The Surveillance, Epidemiology, and End Results (SEER) database was queried from 2004 to 2012. International Classification of Diseases for Oncology (ICD-O) codes identified SCT and LCT. Common germ cell tumors (GCT) provided a reference group. Age, race, histology, tumor size, stage, and cancer-specific mortality (CSM) were compared.

Results: Thirty-one men had SCT, 76 had LCT, and 17,998 had GCTs. Median follow-up for SCT, LCT, and GCTs was 46, 38, and 50 months, respectively. Median ages for SCT and LCT were 39 and 47, respectively, which was older than those with GCT (34 years; P < .001). African American race was more common in SCT (23%) and LCT (24%) patients compared to GCT (3%, P < .001). LCT most commonly presented with stage I disease (98.5%), while patients with SCT presented at higher stages (35% with stage II/III). CSM was highest in patients with SCT (32% vs. 2% LCT and 7% GCT, P < .001). Median survival of those with CSM was similar between SCT, LCT, and GCTs (15, 12, and 14 months, respectively).

Conclusion: Compared to GCT, SCT and LCT present at older ages and are more common in African Americans. Metastasic disease at presentation and CSM rates are higher in SCT compared to LCT and GCT, suggesting a clinically relevant distinction between these histologies. Better characterization of these rare neoplasms will continue to inform patient counseling and management.

Keywords: Demographics; Metastasis; SEER; Sex cord–stromal tumor; Survival.

MeSH terms

  • Adult
  • Age Factors
  • Humans
  • Male
  • Middle Aged
  • Neoplasm Metastasis
  • Neoplasm Staging
  • Neoplasms, Germ Cell and Embryonal / pathology*
  • SEER Program
  • Sertoli-Leydig Cell Tumor / pathology*
  • Survival Analysis
  • Testicular Neoplasms / pathology*
  • Tumor Burden